Princeton Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Princeton Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-56	Closed	-$33K	–	293
2018 Q2	$33K	Buy	+56	New	+$36.5K	0.01%	199

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PWP

Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Princeton Capital Management's HTGM Position: Q3 2018 in Review

Princeton Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2018, closing a stake of 56 shares — an estimated $33K sold.

Princeton Capital Management first reported a position in HTGM in Q2 2018 and held it in 1 quarter. The position peaked at $33K in Q2 2018. 54 funds tracked by Wall St. Rank hold HTGM as of Q3 2018.

Princeton Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Princeton Capital Management sold 56 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2018, an estimated $33K.
Princeton Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
Princeton Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $33K in Q2 2018.
54 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2018.

Based on Princeton Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.